View a one-page version for printing.
SWOG Update
April 2010

Welcome to the April 2010 SWOG Update.

For all members and friends of the Southwest Oncology Group, the SWOG Update will keep you informed of what's happening with the Group. News to report? Send it to

View a one-page version for printing.
Study Updates  
S0941: TKIs against biliary cancers
bile ducts illustration Just launched, S0941 tests combined erlotinib and sorafenib on patients with unresectable or metastasized gallbladder carcinoma or cholangiocarcinoma. [more]
Share |

SELECT Biorepository Symposium, May 4

SELECT trial logo
As the largest prostate cancer prevention trial ever undertaken, the Selenium and Vitamin E Cancer Prevention Trial, or SELECT, has assembled a substantial biorepository of specimens.

To help make SELECT resources available to a wider research community, the Southwest Oncology Group (SWOG) has issued a call for participation in a May 4, 2010, symposium in Dallas to develop an RFP for projects using this biorepository. The symposium will bring together leaders in the major research areas of SELECT to discuss the state of science and outline potential future directions.

Investigators interested in participating should complete the brief application form at

SELECT is an NCI-funded phase III study of the effects of selenium and vitamin E, both separately and together, on the incidence of prostate cancer. The study opened in 2001 and quickly accrued 35,533 men. In the fall of 2008, the trial's Data and Safety Monitoring Committee recommended that participants discontinue taking study supplements based on an interim finding of no preventive benefit. The almost 31,000 participants remaining on SELECT are now being transitioned to a centralized follow-up system to track their health.

The trial's growing biorepository of specimens includes toenail clippings, baseline and post-baseline blood draws, linked nutritional data, adherence cohort data, and a vast clinical database from semiannual visits with each participant.

It also holds prostate biopsies and surgical specimens collected from a subset of the more than 2,100 men who have been diagnosed with prostate cancer during the course of the trial. DNA has been extracted from the serum of these prostate cancer patients and from an age- and race-matched cohort of controls.

Got news to tell? Send it to